1 / 26

CNS -Antiparkinsonian Drugs

CNS -Antiparkinsonian Drugs. Discuss the signs and symptoms exhibited by a patient with Parkinson’s Disease Describe the actions and intended effects of medications used to treat the signs and symptoms of Parkinson’s Disease. CNS Antiparkinsonian Drugs. Parkinson’s Disease:

keanu
Download Presentation

CNS -Antiparkinsonian Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CNS -Antiparkinsonian Drugs • Discuss the signs and symptoms exhibited by a patient with Parkinson’s Disease • Describe the actions and intended effects of medications used to treat the signs and symptoms of Parkinson’s Disease

  2. CNS Antiparkinsonian Drugs • Parkinson’s Disease: • Disease of the basal ganglia & related neuronal groups + neurotransmitter deficiencies • “shaking palsy” • Bradykinesia – slowing down in the initiation & execution of movement • Rigidity – increased muscle tone • Tremor at rest • Impaired postural reflexes

  3. CNS Antiparkinsonian Drugs • Degeneration of dopamine-producing neurons in the substantia nigra of the midbrain • Disrupts the balance of: • dopamine (DA) – neurotransmitter for normal functioning of the extrapyramidal motor system (control of posture, support, and voluntary motion) • Acetylcholine (Ach) • and the basal ganglia • Symptoms do not occur until 80% of the neurons in the substantia nigra are lost

  4. CNS Antiparkinsonian Drugs

  5. CNS Antiparkinsonian Drugs • Five Stages • Flexion of affected arm - tremor / leaning toward unaffected side • Slow shuffling gate • Increased difficulty walking – looks for support to prevent falls • Further progression of weakness – assistance with ambulation • Profound disability – may be confined to wheelchair

  6. CNS Antiparkinsonian Drugs • Tremor • First sign • Affects handwriting – trailing off at ends of words • More prominent at rest • Aggravated by emotional stress or increased concentration • “Pill rolling” – rotary motion of thumb and forefinger • NOT essential tremor – intentional

  7. CNS Antiparkinsonian Drugs • Rigidity • Increased resistance to passive motion when limbs are moved through their range of motion • “Cogwheel rigidity” -- Jerky quality – intermittent catches of movement • Caused by sustained muscle contraction • Muscle soreness; feeling tired & achy • Slowness of movement due to inhibition of alternating muscle group contraction & relaxation in opposing muscle groups

  8. CNS Antiparkinsonian Drugs • Bradykinesia • Loss of automatic movements: • Blinking of eyes, swinging of arms while walking, swallowing of saliva, self-expression with facial and hand movements, lack of spontaneous activity, lack of postural adjustment • Results in: stooped posture, masked face, drooling of saliva, shuffling gait (festination); difficulty initiating movement

  9. CNS Antiparkinsonian Drugs • Drug Therapy • Correcting the imbalance of neurotransmitters within the CNS • Dopaminergic – enhance release or supply of dopamine (DA) • Anticholinergic – antagonize or block the effects of overactive cholinergic neurons in the striatum • Monoamine Oxidase Inhibitor • Decreases MAO (the degradative enzyme for DA) • Results: DA levels are increased • Catechol-O-Methyl Transferase (COMT) Inhibitor • Betablocker • Antihistamine

  10. CNS Antiparkinsonian Drugs

  11. CNS Antiparkinsonian Drugs

  12. CNS Antiparkinsonian Drugs

  13. CNS Antiparkinsonian Drugs

  14. CNS Antiparkinsonian Drugs • Anticholinergic Drugs: decrease the activity of ACh • Artane, Pagitane, Cogentin • Antihistamines – decreases rigidity • Benadryl • Betablockers – decreases rigidity • Inderal • Monoamine oxidase inhibitor (MAO): • Eldepryl, Carbex • Catechol-O-Methyl Transferase (COMT) Inhibitor • Comtan, Tasmar

  15. CNS Antiparkinsonian Drugs • Drug Therapy • Sinemet early in disease becomes ineffective • Early: DA receptor agonist -- directly stimulate DA receptors • Parlodel, Permax, Requip, Mirapex • Moderate to severe symptoms: • Sinemet is added to therapy

  16. CNS Antiparkinsonian Drugs

  17. CNS -- Antiparkinsonian DrugsNursing Process • Assessment • Head-to-toe • Neuro • GI/GU • Ability to swallow • Psychological and emotional coping • Parkinson progression • Medication History • Length of time on medications • Changes in medications and effects • Safety • Ability to perform ADLs independently

  18. CNS -- Antiparkinsonian DrugsNursing Process • Nursing Actions • Exact timing of medication – cannot be administered late • Oral doses given with food • Avoid foods in Vit B6 – reverse effects of levodopa • Force fluids >2,000 mL/day • High roughage, high fiber diet

  19. CNS -- Antiparkinsonian Drugs Patient Education • “Wearing off” phenomenon – gradual worsening of symptoms as medication begins to lose effectiveness, despite maximal doses • “Drug Holiday” when levodopa no longer working effectively (usually 10-day period of hospitalization) • Community resources to assist patient and family • Safety • Effect on blood pressure – • Hypotension • Hypertensive crisis of MAOI accidentally taken • “Sleep attacks” – newer dopamine agonists (pramipexole & ropinirole) • GI: Constipation – high fiber, high roughage, increased fluids • GU: urine color changes – brownish-orange (entacapone)

  20. CNS – Antiparkinsonian DrugsMonitoring Therapeutic Effects • Therapeutic Response: • Improved sense of well being • Ability to perform ADLs • Ability to concentrate and think clearly • Less intense parkinsonian manifestations • Observe for Adverse Effects: • Confusion, anxiety, irritability, depression, paranoia, headache, weakness, lethargy, nausea, vomiting, anorexia, palpitations, postural hypotension, tachycardia, dry mouth, constipation, urinary retention, blurred vision, dark urine, difficulty swallowing, and nightmares

  21. CNS – Antiparkinsonian Drugs • Carbidopa in Parkinson’s disease is to be used: • a. As successful monotherapy. • b. In conjunction with levodopa to block peripheral conversion to dopamine. • c. To decrease the incidence of gastrointestinal side effects associated with levodopa. • d. 2 and 3

  22. CNS – Antiparksonian Drugs • Discuss the normal course of progression of Parkinson’s disease. Include the rationale for drug therapy to alleviate the symptoms.

More Related